Finance

Lists
CRL:BMV
Charles River Laboratories Intrtnl, Inc.
MX$4,720.00
-3.33%
(-162.49) 1D
Aug 14, 11:43:25 AM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Mkt. cap
13.29B
Avg. vol.
1.00
Volume
0.00
52-wk high
MX$5,065.32
52-wk low
MX$2,592.71
No. of employees
19K
Mkt. cap
13.29B
Avg. vol.
1.00
Volume
0.00
52-wk high
MX$5,065.32
52-wk low
MX$2,592.71
No. of employees
19K
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides products and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19K
Founded1947
HeadquartersWilmington, Massachusetts, United States
SectorHealth care
Websitecriver.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.00B
994.23M
995.83M
1.00B
Cost of goods sold
652.72M
665.36M
672.79M
625.06M
Cost of revenue
652.72M
665.36M
672.79M
625.06M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173.64M
192.02M
149.12M
214.18M
Operating expense
201.05M
284.04M
164.46M
227.27M
Total operating expenses
853.77M
949.40M
837.25M
852.33M
Operating income
151.08M
44.83M
158.58M
151.74M
Other non operating income
-22.62M
27.72M
-123.11M
25.99M
EBT including unusual items
87.20M
-294.10M
-29.94M
53.17M
EBT excluding unusual items
104.48M
35.18M
8.62M
148.43M
Income tax expense
31.64M
-17.81M
-15.14M
53.93M
Effective tax rate
36.29%
6.06%
50.56%
101.43%
Other operating expenses
-
-
-
-
Net income
54.42M
-276.56M
-14.84M
-1.48M
Net profit margin
5.42%
-27.82%
-1.49%
-0.15%
Earnings per share
2.43
2.39
2.06
3.02
Interest and investment income
1.42M
1.02M
1.03M
1.03M
Interest expense
-25.40M
-23.78M
-26.74M
-30.34M
Net interest expenses
-23.98M
-22.76M
-25.71M
-29.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
236.25M
169.61M
225.73M
217.54M
Gain or loss from assets sale
-
-
117.98M
24.92M
AI content may include mistakes. Learn more
Google apps